Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • galaberge galaberge Mar 25, 2013 7:14 AM Flag

    Tedizolid Met All Primary and Secondary Efficacy Outcomes Designated by the FDA and EMA. NDA Filing Expected Second Half of This Year.

    "The consistently strong results of the two Phase 3 studies support the promise of tedizolid as a safe and effective new antibiotic, especially in an era of increasing multi-drug resistant Staphylococcus aureus," said Andrew F. Shorr, M.D. MPH, Associate Professor of Medicine, Washington Hospital Center, Washington, D.C. "The potential to treat severe MRSA infections with a novel once-daily agent and a shorter course of therapy offers substantial benefits to patients and, potentially, payers and the healthcare system."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
TSRX
13.630.0000(0.00%)Sep 11 4:00 PMEDT